Detalles de la búsqueda
1.
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Haematologica
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38356463
2.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37102598
3.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32299093
4.
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Blood
; 127(9): 1151-62, 2016 Mar 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-26668134
5.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Blood
; 127(15): 1896-906, 2016 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755711
6.
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Blood
; 127(25): 3165-74, 2016 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27118453
7.
Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
Eur J Haematol
; 99(4): 372-377, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28759125
8.
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 175(3): 448-456, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27434748
9.
Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Eur J Haematol
; 96(4): 417-24, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26190662
10.
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Br J Haematol
; 170(6): 804-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25974382
11.
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Haematologica
; 100(9): 1207-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26069291
12.
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Br J Haematol
; 167(3): 327-36, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25066542
13.
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Blood
; 119(3): 687-91, 2012 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-22128143
14.
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Blood
; 120(8): 1589-96, 2012 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-22791289
15.
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Br J Haematol
; 163(5): 581-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24117042
16.
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Haematologica
; 103(11): e544-e548, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29954938
17.
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Nat Commun
; 14(1): 5825, 2023 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37730678
18.
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Haematologica
; 97(10): 1608-11, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22511492
19.
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
Leuk Lymphoma
; 63(1): 93-100, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34459702
20.
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Blood Cancer J
; 11(5): 101, 2021 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34021118